Fig. 1 · Structure

Documents & Downloads

SEA0400

Cat. No. A15236 CAS 223104-29-8

NCX inhibitor

SEA0400 is a novel and selective inhibitor of the Na+-Ca2+ exchanger with IC50 of 5-33 nM (inhibiting Na+-dependent Ca2+ uptake in cultured neurons, astrocytes, and microglia).

In Stock

Publications for SEA0400

1 publication citing this product

  1. Wakana Shoda, .et al. , PLoS One, 2020, 15(6): e0235360 PMID: 32603346

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

SEA0400 inhibits Na+/Ca2+ exchange in cardiac cells. In guinea-pig ventricular myocytes, the reported EC50 values for inhibition of inward and outward NCX currents were 40 and 32 nM, respectively. Both directions were inhibited under this assay configuration; these values should be interpreted within the tested cellular conditions. [1]

At 1 μM, SEA0400 strongly inhibited NCX current without significant effects on the tested Na+, L-type Ca2+ and K+ channel currents in guinea-pig ventricular myocytes. Partial L-type Ca2+ and inward rectifier K+ current reductions at 10 μM limit broader selectivity claims. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

SEA0400 Research Summary

This section summarizes 5 in vitro studies and 1 in vivo study of SEA0400 from 3 published references.

SEA0400 In Vitro Studies

In NCC-expressing HEK293 cells, 1 μM SEA0400 suppressed the calcium signal triggered by high extracellular potassium and prevented NCC dephosphorylation. A SEA0400-insensitive NCX1 mutant preserved potassium-induced NCC dephosphorylation during treatment, supporting NCX1 involvement in this cellular response. [2]

SEA0400 effects depended on NCX expression in isolated mouse ventricular myocytes. It slowed NCX-associated calcium removal in all tested lines. In paced cells, spontaneous calcium releases decreased in NCX-overexpressing cells but increased in cells with normal or reduced NCX expression; the event-count increase in one wild-type line was a nonsignificant trend. Knockout-line cells showed frequent calcium hypercontraction and subsequent cell death. These cellular readouts do not establish whole-heart antiarrhythmic efficacy. [3]

Inhibition of native cardiac NCX current

Cell-based study · Isolated ventricular myocytes from male guinea pigs; whole-cell voltage clamp [1]

SEA0400 inhibited both inward and outward Ni2+-sensitive NCX currents. Potency values are assay endpoints, not treatment doses. KB-R7943 was tested separately as comparator.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of inward current at −80 mV and outward current at +30 mVEC50 (paper terminology) 40 nM inward; 32 nM outward[1]
NCX current remaining at 1 μM SEA0400, relative to drug-free currentResidual current 17.5 ± 0.6% inward; 13.4 ± 3.2% outward[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response experiment; 1 μM SEA0400 quantified in Results
Exposure duration
Drug-exposure duration not specified in text
Method
Bath application during ramp voltage clamp at 35–36°C; Ni2+-sensitive current defined using 5 mM Ni2+
Co-treatment
No combined inhibitor treatment; KB-R7943 tested separately
Reported limits
Vehicle and a fixed SEA0400 equilibration time not specified in the inspected Methods/Results.
Methods and source locations

Compound reported in the paper: SEA0400

Reported SEA0400 material and experimental model only; no product-lot equivalence or human efficacy established.

Methods; Table 1; Results: Effect of SEA0400 and KB-R7943 on NCX current; Figure 1A–E

Inhibition of inward current at −80 mV and outward current at +30 mV: Interpolation between two data points near 50% inhibition; means ± SEM in Figure 1, n = 3–4 experiments, cells from different animals. — Methods; Results: NCX current; Figure 1E

NCX current remaining at 1 μM SEA0400, relative to drug-free current: Mean ± SEM; Figure 1 caption gives n = 3–4 experiments. Not percentages of inhibition. — Results: NCX current; Figure 1A,C,E

Ion-current selectivity within the tested cardiac panel

Cell-based study · Isolated male guinea-pig ventricular myocytes; separate whole-cell recordings for Na+, L-type Ca2+, inward rectifier K+ and delayed rectifier K+ currents [1]

At 1 μM, SEA0400 had no significant effect on the four tested channel currents. At 10 μM, partial reductions in L-type Ca2+ and inward rectifier K+ currents limited concentration-independent selectivity claims.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Four ionic current amplitudes after 1 μM SEA0400, relative to drug-free currentResidual current Na+: 96.0 ± 1.1%; L-type Ca2+: 91.0 ± 2.2%; inward rectifier K+: 96.0 ± 2.5%; delayed rectifier K+: 98.0 ± 10.0%[1]
Additional channel responses to 10 μM SEA0400Residual current L-type Ca2+: 77.3 ± 5.0% (n = 5); inward rectifier K+: 87.7 ± 3.5% (n = 4); delayed rectifier K+: 102.8 ± 4.0% (n = 5)[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM SEA0400; additional 10 μM SEA0400 channel tests
Exposure duration
Fixed exposure time not specified in text
Method
Whole-cell voltage clamp; Na+ current at 22–23°C, other currents at 35–36°C
Co-treatment
KB-R7943 (10 μM) is a separate comparator, not co-treatment
Reported limits
Vehicle and fixed equilibration time not specified in inspected Methods/Results.
Methods and source locations

Compound reported in the paper: SEA0400

Reported SEA0400 material and experimental model only; no product-lot equivalence or human efficacy established.

Methods; Table 1; Results: Effect of SEA0400 and KB-R7943 on ion channel currents; Figures 2–5

Four ionic current amplitudes after 1 μM SEA0400, relative to drug-free current: Mean ± SEM, n = 4 per figure captions; paired t-test. Endpoints at −20 mV, +10 mV, −60 mV, and tail after +50 mV, respectively. — Results: ion channel currents; Figures 2–5

Additional channel responses to 10 μM SEA0400: Mean ± SEM; relative to current in absence of drug. Text-reported values; no unshown graph inferred. — Results: ion channel currents, final paragraph; Discussion

SEA0400 suppresses potassium-evoked calcium signaling and NCC dephosphorylation

Cell-based study · Flp-In NCC HEK293 cells; CaN-B overexpressed for NCC-dephosphorylation experiments unless otherwise stated [2]

At 1 μM, SEA0400 suppressed the high-K+-evoked Fluo-4 response and prevented NCC dephosphorylation. In the specificity-control extension, K+-induced NCC dephosphorylation remained detectable in cells expressing SEA0400-insensitive F213L NCX1 despite SEA0400 treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
K+-evoked intracellular calcium signalQualitative Fluo-4 response Increase suppressed by 1 μM SEA0400; 1 μM nifedipine did not suppress the displayed response[2]
K+-induced change in phosphorylated NCC relative to total NCCImmunoblot response SEA0400 prevented the high-K+-induced decrease in pNCC/tNCC; F213L NCX1 expression restored a significant high-K+ response under SEA0400[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM SEA0400
Exposure duration
1 h pretreatment before K+ stimulation; Fluo-4 image at 30 s after stimulation
Method
High-K+ challenge (10 mM final) versus normal K+ (3 mM); Fluo-4 imaging and phospho-NCC/total-NCC immunoblotting
Co-treatment
High-K+ stimulus; CaN-B expression in NCC assays; F213L versus wild-type NCX1 specificity control
Reported limits
SEA0400 vehicle for cultured-cell experiments and fixed high-K+ incubation duration for Figure 3C are not explicitly specified in its caption; no time borrowed from another figure.
Methods and source locations

Compound reported in the paper: SEA0400

Reported SEA0400 material and experimental model only; no product-lot equivalence or human efficacy established.

Materials and methods: Cell culture and transfections, Intracellular calcium assay, Western blotting; Results: Reverse-mode NCX plays a role in the Ca2+ influx pathway; Figure 3B,C; S8 Figure; S1 File

K+-evoked intracellular calcium signal: Representative imaging at 30 s and time course; no replicate number or inferential statistic specified for Figure 3B. — Figure 3B and caption; Intracellular calcium assay; Results: Reverse-mode NCX

K+-induced change in phosphorylated NCC relative to total NCC: n = 6 per figure caption; mean ± SEM per general statistics; p < 0.05 for indicated normal/high-K+ comparison, Tukey after two-way ANOVA; no exact band ratios inferred. — Figure 3C and caption; S8 Figure and caption; S1 File immunoblot methods

Forward-mode NCX functional readout in genetically distinct myocytes

Cell-based study · Isolated ventricular cardiomyocytes from NCX-overexpressing (OE), heterozygous knockout (hetKO) mice and their respective wild-types; mice <12.5 weeks [3]

SEA0400 increased the time to half-decay of caffeine-induced calcium transients in all four lines, consistent with reduced forward-mode NCX-mediated calcium removal.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Time to 50% decay of caffeine-induced Ca2+ transientT50 (s) Basal → 1 μM SEA0400: OE 1.2 ± 0.2 → 2.9 ± 0.4; WTOE 2.0 ± 0.1 → 4.1 ± 0.4; hetKO 3.3 ± 0.2 → 5.8 ± 0.4; WThetKO 2.1 ± 0.2 → 4.3 ± 0.4[3]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM SEA0400
Exposure duration
Before caffeine: 1 Hz field stimulation for 1 min then 10 s rest; fixed drug-equilibration interval not specified
Method
10 mM caffeine challenge; Fluo-4-AM calcium imaging at room temperature
Co-treatment
Caffeine as readout stimulus, not a therapeutic combination
Reported limits
Supplier, chemical form, vehicle and fixed drug-equilibration time are not specified in the inspected article.
Methods and source locations

Compound reported in the paper: SEA0400

Reported SEA0400 material and experimental model only; no product-lot equivalence or human efficacy established.

Methods: NCX transgenic mouse models, Ca2+ epifluorescence measurements, Statistics; Results: Effects of SEA0400 on NCX-mediated Ca2+ removal; Figure 1

Time to 50% decay of caffeine-induced Ca2+ transient: Mean ± SEM; n cells/mice basal → drug: OE 37/5 → 21/3; WTOE 42/5 → 25/3; hetKO 26/4 → 24/3; WThetKO 24/4 → 24/3. All drug versus basal p < 0.05, ANOVA on ranks; arrows do not imply a paired sample of identical cells. — Results: Effects of SEA0400 on NCX-mediated Ca2+ removal; Figure 1B,D

NCX-expression-dependent calcium responses and adverse cellular events

Cell-based study · Isolated OE, hetKO, WTOE and WThetKO ventricular cardiomyocytes; mice <12.5 weeks; indo-1-AM imaging [3]

SEA0400 increased stimulated calcium-transient amplitude in wild-types and hetKO, but not OE. It decreased spontaneous release events in OE while increasing events in WThetKO and hetKO; WTOE showed a nonsignificant upward trend in event count. Hypercontraction with subsequent cell death was especially frequent in hetKO.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Field-stimulated calcium-transient amplitude relative to basalDirection and significance At 1 μM, amplitude increased in WTOE, WThetKO and hetKO (p < 0.05 versus basal), with no significant increase in OE[3]
Spontaneous calcium releases per analyzed cell during 0.125 Hz pacingEvents/cell Basal → 1 μM: OE 12.5 ± 3.8 → 3.7 ± 1.0; WTOE 0.2 ± 0.1 → 2.4 ± 0.8; WThetKO 1.3 ± 1.0 → 8.8 ± 1.9; hetKO 0.2 ± 0.2 → 5.5 ± 2.2[3]
Cells with abrupt calcium hypercontraction and subsequent cell death during 1 μM SEA0400Fraction hetKO 58%; WThetKO 11%; OE 15%; WTOE 19%[3]

Literature-Reported Treatment Conditions

Treatment concentration
Sequential 0.3 and 1 μM SEA0400; adverse-event results at 1 μM
Exposure duration
Each sequence: 1 Hz stimulation for 4 min followed by 20 sweeps at 0.125 Hz; repeated within the same cell after drug addition
Method
Indo-1-AM imaging at room temperature; basal/drug comparisons
Reported limits
Supplier, chemical form, vehicle and separate equilibration interval are not specified in inspected text.
Methods and source locations

Compound reported in the paper: SEA0400

Reported SEA0400 material and experimental model only; no product-lot equivalence or human efficacy established.

Methods: Ca2+ epifluorescence measurements and Statistics; Results: Ca2+ transient amplitude and spontaneous Ca2+ transients; Figures 2–4; Limitations

Field-stimulated calcium-transient amplitude relative to basal: Steady-state end of 1 Hz pacing; mean ± SEM; repeated-measures ANOVA. At 1 μM n cells/mice: OE 23/8; WTOE 23/7; hetKO 9/3; WThetKO 16/4. Amplitude is a proxy; direct contractility not measured. — Results: Effects of SEA0400 on the Ca2+ transient amplitude; Figure 2

Spontaneous calcium releases per analyzed cell during 0.125 Hz pacing: Mean ± SEM; repeated-measures ANOVA: significant drug changes in OE, WThetKO and hetKO; WTOE upward trend. n cells/mice basal → drug: OE 27/8 → 23/8; WTOE 27/7 → 23/7; WThetKO 19/4 → 16/4; hetKO 19/5 → 8/3. — Results: Influence of SEA0400 on proarrhythmic spontaneous Ca2+ transients; Figure 3B

Cells with abrupt calcium hypercontraction and subsequent cell death during 1 μM SEA0400: hetKO versus WThetKO p < 0.05; OE versus WTOE p > 0.05, Fisher exact test in Results. Only 42% of measured hetKO cells remained analyzable; event-count/amplitude data therefore reflect surviving analyzable cells. No denominator invented. — Results: Influence of SEA0400, final paragraph; Figure 4; Limitations

SEA0400 In Vivo Studies

In adult male mice given an acute oral potassium load, SEA0400 (10 mg/kg intraperitoneally, 1 h beforehand) inhibited rapid renal NCC dephosphorylation and reduced urinary potassium excretion at 30 and 90 min. Blood potassium at 120 min was higher with SEA0400 than with vehicle (6.5 ± 0.4 versus 5.5 ± 0.2 mmol/l; mean ± SEM, N = 6 per group). This experiment identifies a renal potassium-handling effect and a potentially adverse physiological consequence of NCX inhibition in this setting. [2]

Renal and blood responses during acute potassium loading

Animal study · Adult male C57BL/6 mice, 23–25 g; vehicle/SEA0400 × control/high-K+ groups [2]

SEA0400 attenuated renal NCC dephosphorylation after an acute K+ load and reduced urinary K+ excretion at specified time points. Blood K+ was higher at 120 min, an adverse physiological direction in this setting.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Renal phosphorylated NCC/total NCC 15 min after K+ loadImmunoblot response Rapid K+-induced NCC dephosphorylation was inhibited by SEA0400; total NCC showed no significant change in the displayed comparisons[2]
Cumulative urinary electrolyte excretion after K+ loadTime-specific comparison K+ excretion significantly lower with SEA0400 at 30 and 90 min; Na+ lower at 30 min; Cl− differences not statistically significant[2]
Blood K+ 120 min after K+ oral gavageConcentration High-K+: vehicle 5.5 ± 0.2 mmol/l; SEA0400 6.5 ± 0.4 mmol/l; control load: vehicle 4.8 ± 0.2 mmol/l, SEA0400 4.7 ± 0.1 mmol/l[2]

Conditions shared by the study groups

Route
Intraperitoneal injection
Frequency
Single injection
Treatment course
1 h before K+ oral gavage; kidney endpoint 15 min after gavage, urine collected every 30 min through 120 min, blood at 120 min
Vehicle
Mixture of 5% DMSO and 5% gum Arabic
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
SEA0400 with acute oral potassium load
10 mg/kg
Vehicle-treated high-K+ mice; vehicle and SEA0400 groups given control 2% sucrose solution also includedSuppressed rapid renal NCC dephosphorylation and urinary K+ excretion after the K+ load; higher blood K+ at 120 min.[2]
SEA0400 with acute oral potassium load
Model: Adult male C57BL/6 mice, 23–25 g
Reported limits: Age in weeks and randomization/blinding are not specified in inspected animal Methods.
Methods and source locations

Compound reported in the paper: SEA0400

Reported SEA0400 material and experimental model only; no product-lot equivalence or human efficacy established.

Animal experiments; Figure 6A,B and caption; Table 2; Results: Blockade of NCX1 inhibited rapid NCC dephosphorylation; Discussion

Renal phosphorylated NCC/total NCC 15 min after K+ load: n = 6; mean ± SEM; indicated p < 0.05, Tukey after two-way ANOVA. No exact band ratios inferred. — Figure 6A and caption; Animal experiments

Cumulative urinary electrolyte excretion after K+ load: n = 6; mean ± SEM; p < 0.05 at indicated time points, Tukey after two-way ANOVA. Graph ordinate unit is questionable; absolute excretion values are not extracted. — Figure 6B and caption; Results: Blockade of NCX1; Discussion

Blood K+ 120 min after K+ oral gavage: Mean ± SEM, N = 6 per group. Results explicitly state significantly higher blood K+ with SEA0400 under high-K+ loading; Table 2 uses two-way ANOVA with Tukey, p < 0.05. — Table 2; Results: Blockade of NCX1, paragraph immediately before Table 2

SEA0400 with acute oral potassium load · Animal experiments; Figure 6A,B; Table 2; Results: Blockade of NCX1

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 223104-29-8
Applications NCX inhibitor
Formula C21H19F2NO3
Molecular Weight 371.38
SMILES
CCOC1=CC(=C(C=C1)OC2=CC=C(C=C2)OCC3=C(C=CC(=C3)F)F)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 63 mg/mL (169.63 mM)
Water Insoluble
Ethanol 63 mg/mL (169.63 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

SEA0400 Research References

  1. [1] Tanaka H, Nishimaru K, Aikawa T, et al. Effect of SEA0400, a novel inhibitor of sodium-calcium exchanger, on myocardial ionic currents British Journal of Pharmacology (2002). PMID: 11877314 DOI: 10.1038/sj.bjp.0704574 Source material
  2. [2] Shoda W, Nomura N, Ando F, et al. Sodium–calcium exchanger 1 is the key molecule for urinary potassium excretion against acute hyperkalemia PLOS ONE (2020). PMID: 32603346 DOI: 10.1371/journal.pone.0235360 Source material
  3. [3] Bögeholz N, Schulte JS, Kaese S, et al. The Effects of SEA0400 on Ca2+ Transient Amplitude and Proarrhythmia Depend on the Na+/Ca2+ Exchanger Expression Level in Murine Models Frontiers in Pharmacology (2017). PMID: 28983248 DOI: 10.3389/fphar.2017.00649 Source material

Publications

1 publication citing this product

  1. Wakana Shoda, .et al. , PLoS One, 2020, 15(6): e0235360 PMID: 32603346

Added to your cart

View Cart Checkout
Loading...